Xiidra Alternatives Compared
| Xiidra (lifitegrast) | Restasis (cyclosporine) | Cyclosporine ophthalmic |
|
|---|
| Xiidra (lifitegrast) | Restasis (cyclosporine) | Cyclosporine ophthalmic |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Xiidra is a prescription eye drop that may be used to reduce inflammation associated with dry eye disease. The main side effects are eye irritation or redness and an unusual taste in the mouth... View more |
Prescription only
Prescribed for Dry Eye Disease. Restasis may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Dry Eye Disease, Keratoconjunctivitis. Cyclosporine ophthalmic may also be used for purposes not listed in this medication guide. |
Related suggestions Dry Eye Disease (Keratoconjunctivitis Sicca)
Popular comparisons
|
|||||||||||||||||||||||
| More about Xiidra (lifitegrast) | More about Restasis (cyclosporine) | More about Cyclosporine ophthalmic | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Xiidra has an average rating of 4.3 out of 10 from a total of 449 ratings on Drugs.com. 27% of reviewers reported a positive effect, while 52% reported a negative effect. |
Restasis has an average rating of 4.6 out of 10 from a total of 224 ratings on Drugs.com. 26% of reviewers reported a positive effect, while 47% reported a negative effect. |
Cyclosporine ophthalmic has an average rating of 4.7 out of 10 from a total of 286 ratings on Drugs.com. 27% of reviewers reported a positive effect, while 46% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Xiidra side effects |
View all Restasis side effects |
View all Cyclosporine ophthalmic side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Xiidra prices |
View all Restasis prices |
View all Cyclosporine ophthalmic prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
Other cyclosporine brands include: Cequa, Verkazia, Vevye | Cequa, Restasis, Verkazia, Vevye | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
No known drug interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
A total of 15 drugs are known to interact with Restasis:
|
A total of 15 drugs are known to interact with Cyclosporine ophthalmic:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
July 11, 2016 |
December 23, 2002 |
December 23, 2002 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.